普遍发放阿司匹林预防高风险人群子痫前期
一项观察性队列研究纳入Parkland Health 2020年4月至2025年7月全部分娩,比较实施普遍发放162 mg/d阿司匹林前后各18,457例患者。阿司匹林期子痫前期伴严重特征发生率更低(6.9% vs 5.1%,P<.001),调整OR 0.65(0.60-0.72),慢性高血压患者调整OR 0.72(0.59-0.86),且未增加胎盘早剥、产后出血及新生儿并发症。
要点
- 高风险人群普遍发放阿司匹林与子痫前期伴严重特征发生率降低相关。
- 慢性高血压患者同样获益,调整OR 0.72(0.59-0.86)。
- 未观察到胎盘早剥、产后出血及新生儿并发症增加。
核心结论
- 在高妊娠期高血压疾病发生率人群中,首次产检时普遍发放162 mg/d阿司匹林与子痫前期伴严重特征的人群水平下降相关,且不增加胎盘早剥或产后出血。
研究设计与样本
- 观察性队列研究,纳入2020年4月至2025年7月Parkland Health全部分娩,比较实施普遍发放阿司匹林前后两个各18,457例患者的队列,排除2022年8月3日至2023年2月3日洗脱期分娩。
主要发现
- 阿司匹林期子痫前期伴严重特征发生率为5.1%,对照期为6.9%(P<.001),调整OR 0.65(0.60-0.72)。
- 阿司匹林期子痫前期伴严重特征诊断时间更长(P<.001)。
- 慢性高血压患者阿司匹林期发生子痫前期伴严重特征的调整OR为0.72(0.59-0.86)。
- 阿司匹林期胎盘早剥、产后出血及新生儿并发症发生率未增加。
- 药房数据显示,后期队列中至少14,754例(80.4%)在≤16周有产检的患者接受了阿司匹林,中位发放180片。
关键数值与推荐
- 在≤16周开始产检的患者自2022年8月3日起每日接受162 mg阿司匹林;此前不推荐阿司匹林 regardless of risk factors。
- 主要结局为子痫前期伴严重特征,定义为因严重高血压、实验室异常或子痫而使用硫酸镁的临床诊断。
临床怎么用
- 在高妊娠期高血压疾病负担人群中,可考虑在首次产检时普遍发放162 mg/d阿司匹林以预防子痫前期伴严重特征,尤其适合能直接发药的产检机构。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hypertensive disorders of pregnancy are a major cause of maternal morbidity and mortality. Aspirin therapy has shown benefit in high-risk populations; however, current characteristic-based screening approaches are cumbersome, and the risks of aspirin exposure are low, making universal prescribing appealing. OBJECTIVE: To report the effect of universal aspirin dispensation for preeclampsia prevention in a population with a high rate of hypertensive disorders. STUDY DESIGN: This observational cohort study includes all deliveries between April 2020 and July 2025 at Parkland Health, a high-volume obstetric service with community clinics capable of directly dispensing medication during prenatal visits. Patients who initiated prenatal care by 16 weeks gestation received 162 mg aspirin daily beginning August 3, 2022; prior to this date, aspirin was not recommended regardless of risk factors. Deliveries during the washout period (August 3, 2022-February 3, 2023) were excluded. The primary outcome was preeclampsia with severe features, which was a clinical diagnosis characterized by the administration of magnesium sulfate for severe hypertension, lab abnormalities, or eclampsia. RESULTS: Two cohorts of 18,457 patients, before and after aspirin implementation, were compared. Patients in the aspirin epoch had a lower incidence of preeclampsia with severe features (6.9% vs 5.1%, P<.001), adjusted odds ratio of 0.65 (0.60-0.72). In addition, the time to diagnosis of preeclampsia with severe features was longer in the aspirin epoch (P<.001). Patients with chronic hypertension were also less likely to develop preeclampsia with severe features, with an adjusted odds ratio of 0.72 (0.59-0.86) in the aspirin epoch. The rates of abruption, postpartum hemorrhage, and neonatal complications did not increase in the aspirin epoch. Pharmacy data confirmed that at least 14,754 (80.4%) patients with a prenatal visit at ≤16 weeks received aspirin during the later epoch, with a median of 180 tablets dispensed. CONCLUSION: Universal dispensation of 162 mg aspirin daily at the first prenatal visit in a population with a high rate of hypertensive disorders was associated with a population-level reduction in the development of preeclampsia with severe features in patients with and without chronic hypertension, without an increase in abruption or postpartum hemorrhage. This study demonstrates the possible benefit of a universal approach to aspirin prescribing in high-risk populations, especially if direct dispensation is performed.
引用
- Duryea E, Ambia A, Pruszynski J, et al. Universal aspirin dispensation for prevention of preeclampsia in a high-risk population. Am J Obstet Gynecol. 2026. PMID: 42660215. doi:10.1016/j.ajog.2026.08.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。